Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical application of enzymatic hydrolysate of icariin and main component baohuoside I of icariin

A technology of icariin and enzymatic hydrolysis product, which is applied in the fields of medicine and traditional Chinese medicine

Inactive Publication Date: 2020-12-29
SHANGHAI UNIV OF T C M
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there have been many reports on the therapeutic effect of Epimedium and its chemical components on osteoporosis recently, there is no evidence that the enzymatic hydrolyzate of icariin and its main component, baojoside I, are used in the prevention and treatment of skeletal muscular atrophy. application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of enzymatic hydrolysate of icariin and main component baohuoside I of icariin
  • Medical application of enzymatic hydrolysate of icariin and main component baohuoside I of icariin
  • Medical application of enzymatic hydrolysate of icariin and main component baohuoside I of icariin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] A preparation method of an enzymatic hydrolysis product of icariin (the main component is baojoside I), the specific steps of which are as follows:

[0032] Weigh about 50 mg of icariin and β-glucosidase, dissolve in 10 mL of 0.2M acetic acid buffer solution with pH=4.0 and stir at 40°C for 8 hours, extract the reaction solution with 50 mL of ethyl acetate for 3 times, collect the upper layer solution, and use Dried over sodium sulfate, concentrated by rotary evaporation, transferred the concentrated solution to a refrigerator at 4°C for static crystallization; dried the crystals in a vacuum at 40°C for 3 hours to obtain the crude product of baochoside I; recrystallized from methanol to obtain the refined product of baochoside I The crude and refined products of glycoside I are the enzymatic hydrolysis products of icariin).

[0033] Adopt HPLC to detect the content of baochoside I in the enzymatic hydrolysis product of icariin (crude product and refined product of baoch...

Embodiment 2

[0035] Test the protective effect of icariin hydrolyzate and baohuoside I on C2C12 myotube cell atrophy induced by dexamethasone:

[0036] The preventive effect of baohuoside I on the myotube cell atrophy model induced by dexamethasone by pre-administration was tested.

[0037] (1) Test method

[0038] A. C2C12 cells were treated with 100 μM Dex (dexamethasone) for 24 hours to establish a model, which was used as a model group (dexamethasone group). Separately set different concentrations of traditional Chinese medicine monomer groups, the specific method is: add different concentrations of baohuoside I (Icarisid II) 12 hours in advance of adding dexamethasone, so that the final concentration is 100, 200, 500, 1000nM, and different concentrations The final concentration of icariin hydrolyzate (Icarisid M) was 300, 800 nM.

[0039] Results: Compared with the dexamethasone group, each concentration of Icarisid II and Icarisid M could promote cell proliferation, and the concent...

Embodiment 3

[0057] Test the protective effect of icariin hydrolyzate and baohuoside I on dexamethasone-induced skeletal muscle atrophy in mice:

[0058] The enzymatic hydrolysis product of icariin and baohuoside I were tested for the prevention of dexamethasone-induced skeletal muscle atrophy in mice by intragastric administration.

[0059] (1) Test method

[0060] Normal group (abbreviated as Normal): intraperitoneal injection of normal saline, and gavage of 50 μl of 0.1% ethanol at the same time, for 14 consecutive days, once a day. Model group (Dex for short): intraperitoneal injection of dexamethasone solution, 1 mg / kg.day, and 50 μl of 0.1% ethanol, for 14 consecutive days, once a day. Baohuoside I group (referred to as Dex+Icarisid II) intraperitoneally injected dexamethasone solution, 1mg / kg.day, and at the same time 0.005mg / 10g body weight 0.005mg / 10g Baohuoside I solution 50 microliters into the stomach, continuous perfusion for 14 days, 1 times / day. Icariin hydrolyzate group ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medical application of an enzymatic hydrolysate of icariin and a main component baohuoside I of the icariin, and particularly relates to an application of the enzymatic hydrolysate of icariin and the main component baohuoside I of the icariin in preparing a medicine for treating skeletal muscle atrophy. In-vitro and in-vivo experiments prove that the enzymatic hydrolysateof icariin or baohuoside I can significantly reduce the skeletal muscle atrophy degree, including increase of muscle fiber cross-sectional area, gastrocnemius muscle wet weight / body mass ratio and aerobic exercise ability, and can up-regulate skeletal muscle protein content by regulating an autophagy system, thus having great application prospects.

Description

technical field [0001] The invention belongs to the technical field of medicine and traditional Chinese medicine, and relates to the medical application of an enzymatic hydrolyzate of icariin and its main component Baohuoside I, in particular to an enzymatic hydrolyzate of icariin and its main component Baohuo Application of glycoside I in the preparation of medicines for treating skeletal muscle atrophy. Background technique [0002] Epimedium is a commonly used clinical traditional Chinese medicine. The whole herb is used for medicinal purposes. It is also known as Xianlingpi and Gangqian. It is listed as a middle-grade product in "Shen Nong’s Herbal Classic". Caused by impotence and nocturnal emission, flaccidity of muscles and bones, rheumatic arthralgia, numbness and contracture. Icariin (ICA), the main chemical component of Epimedium herba, has various pharmacological activities such as anti-osteoporosis, immune regulation, anti-tumor and improvement of cardiovascular...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P21/00C12P19/60
CPCA61K31/7048A61P21/00C12P19/60A61K2300/00
Inventor 张彤龚张斌丁越
Owner SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com